News

ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a no objection letter (NOL) from Health Canada to an Amendment of the Company’s Phase 1 clinical trial of RLS-0071 in healthy volunteers. The study design has been modified to add three multiple ascending dose (MAD) cohorts and an additional single ascending high dose (SAD) cohort to the trial.

“The revised trial design amendment will enable us to expeditiously execute the SAD and MAD parts of this Phase 1 clinical trial and obtain important PK-PD, safety and tolerability data that will inform future Phase 2 clinical trial protocols addressing our target indications,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “We look forward to providing additional updates on the trial and obtaining data from this study as it progresses and continues to support our other programs.”

Prior to the amendment, the Phase 1 trial was a single ascending dose randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK and PD of RLS-0071 in healthy subjects.

Recent News

02/29/2024

VCU Health leads clinical trial for new treatment to help people with bowel control problems

A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels. The implantation surgery for the clinical trial

02/22/2024

Don’t Miss These Spring Talent Events

We’ve compiled a calendar of events happening this spring aimed at connecting talented people in the biosciences. Feb. 27: Internship Support for Employers: V-TOP Staffing Agency + Matching Funds | Virtual Employers can tune in to learn more internship support through V-TOP’s partnership with iQuasar, the statewide staffing agency and how to utilize their matching funds

02/21/2024

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.